Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Antibody
Sort By
Newest First
Sign in
1 / 1
1 / 1
Antibody
Timberlyne Therapeutics Secures $180M Series A to Advance CM313, a Promising Anti-CD38 Antibody for High-Need Diseases.
Timberlyne Therapeutics
PR-01-25-NI-07
Jan 10, 2025
Agreement
Mediar Therapeutics and Lilly Sign Global Licensing Agreement to Advance WISP1 Antibody to Treat Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
PR-01-25-NI-06
Jan 10, 2025
Antibody
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Spyre Therapeutics, Inc.
PR-12-24-NI-125
Dec 03, 2024
Financing
EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
EQT
PR-11-24-NI-116
Nov 20, 2024
ADC
Chime Biologics and Waterstone Jointly Develop and Manufacture Antibody-Drug Conjugate (ADC)
Chime Biologics
PR-10-24-NI-91
Nov 12, 2024
Announcement
Celebrating More than a Decade of Excellence at the World ADC Awards – Winners Announcement
World ADC
PR-10-24-NI-77
Nov 08, 2024
